Cargando…

Anticancer activity of 1,25-(OH)(2)D(3) against human breast cancer cell lines by targeting Ras/MEK/ERK pathway

PURPOSE: Breast cancer is the most common cancer among women with ~1.67 million cases diagnosed annually worldwide, and ~1 in 37 women succumbed to breast cancer. Over the past decades, new therapeutic strategy has substantially improved the curative effect for women with breast cancer. However, the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Wei, Cao, Lin, Ouyang, Linna, Zhang, Qian, Duan, Bofeng, Zhou, Wei, Chen, Shan, Peng, Wei, Xie, Yi, Fan, Qing, Gong, Daoxing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348968/ https://www.ncbi.nlm.nih.gov/pubmed/30774359 http://dx.doi.org/10.2147/OTT.S190432

Ejemplares similares

Association among plasma 1,25(OH)(2)D, ratio of 1,25(OH)(2)D to 25(OH)D, and prostate cancer aggressiveness
por: Ramakrishnan, Swathi, et al.
Publicado: (2019)

Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer
por: Gonzalez-Hormazabal, Patricio, et al.
Publicado: (2018)

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
por: Degirmenci, Ufuk, et al.
Publicado: (2020)

Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway
por: Kochetkova, Elena Y., et al.
Publicado: (2017)

Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition
por: Catalano, Antonella, et al.
Publicado: (2021)

Reusability and composability in process description maps: RAS–RAF–MEK–ERK signalling
por: Mazein, Alexander, et al.
Publicado: (2021)

Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations
por: Vlot, Mariska C, et al.
Publicado: (2019)

Vitamin D and 1,25(OH)(2)D Regulation of T cells
por: Cantorna, Margherita T., et al.
Publicado: (2015)

Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A(3) adenosine receptor
por: Merighi, Stefania, et al.
Publicado: (2006)

The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
por: Li, Lei, et al.
Publicado: (2016)

RDM1 promotes neuroblastoma growth through the RAS–Raf–MEK–ERK pathway
por: Xie, Guojin, et al.
Publicado: (2019)

Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
por: Avery, Thomas Yul, et al.
Publicado: (2022)

25(OH)D and 1,25(OH)D vitamin D fails to predict sepsis and mortality in a prospective cohort study
por: Ratzinger, Franz, et al.
Publicado: (2017)

Reversal of the Ras-Induced Transformed Phenotype by Hr12, a Novel Ras Farnesylation Inhibitor, Is Mediated by the Mek/ERK Pathway
por: Reuveni, Hadas, et al.
Publicado: (2000)

The MEK-ERK Pathway Is Necessary for Serine Phosphorylation of Mitochondrial STAT3 and Ras-Mediated Transformation
por: Gough, Daniel J., et al.
Publicado: (2013)

Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
por: Merchant, Mark, et al.
Publicado: (2017)

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation
por: Xu, J, et al.
Publicado: (2017)

Antidepressants differentially related to 1,25-(OH)(2) vitamin D(3) and 25-(OH) vitamin D(3) in late-life depression
por: Oude Voshaar, R C, et al.
Publicado: (2014)

Does Sevelamer Hydrochloride (Renagel) Influence 25(Oh)D3 and 1,25(Oh)2D3 Level in Haemodialysis Patients?
por: Strózecki, Pawel, et al.
Publicado: (2005)

25(OH)D(3) and 1.25(OH)(2)D(3) inhibits TNF-α expression in human monocyte derived macrophages
por: Rafique, Aisha, et al.
Publicado: (2019)

MON-LB74 The Problem of Measuring 1,25(OH)2 Vitamin D in Patients With High Levels of 25(OH) Vitamin D
por: Vieira, Jose Gilberto, et al.
Publicado: (2020)

Circulatory 25(OH)D and 1,25(OH)(2)D as differential biomarkers between multiple system atrophy and Parkinson's disease patients
por: Ogura, Hiromu, et al.
Publicado: (2021)

25(OH)D-but not 1,25(OH)(2)D–Is an independent risk factor predicting graft loss in stable kidney transplant recipients
por: Zeng, Shufei, et al.
Publicado: (2023)

1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)(2)D(3) in NSCLC Treatment
por: Upadhyay, Santosh Kumar, et al.
Publicado: (2013)

Design, Synthesis, and Antileukemic Evaluation of a Novel Mikanolide Derivative Through the Ras/Raf/MEK/ERK Pathway
por: Rao, Qing, et al.
Publicado: (2022)

1,25-(OH)(2)D(3)/Vitamin D receptor alleviates systemic lupus erythematosus by downregulating Skp2 and upregulating p27
por: Liu, Dan, et al.
Publicado: (2019)

PI3 kinase is important for Ras, MEK and Erk activation of Epo-stimulated human erythroid progenitors
por: Schmidt, Enrico K, et al.
Publicado: (2004)

Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting
por: Knight, Thomas, et al.
Publicado: (2014)

Correction: The MEK-ERK Pathway Is Necessary for Serine Phosphorylation of Mitochondrial STAT3 and Ras-Mediated Transformation
por: Gough, Daniel J., et al.
Publicado: (2013)

Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
por: Merchant, Mark, et al.
Publicado: (2018)

Targeting the effect of sofosbuvir on selective oncogenes expression level of hepatocellular carcinoma Ras/Raf/MEK/ERK pathway in Huh7 cell line
por: Atif, Muhammad, et al.
Publicado: (2022)

The metabolism of 1,25(OH)(2)D(3) in clinical and experimental kidney disease
por: Turner, Mandy E., et al.
Publicado: (2022)

Antitumor effects and mechanisms of 1,25(OH)(2)D(3) in the Pfeiffer diffuse large B lymphoma cell line
por: Han, Jing, et al.
Publicado: (2019)

CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response
por: Dixon, Zach A., et al.
Publicado: (2017)

Effects of 1,25(OH)(2)D(3) and 25(OH)D(3) on C2C12 Myoblast Proliferation, Differentiation, and Myotube Hypertrophy
por: van der Meijden, K., et al.
Publicado: (2016)

Vitamin D (1,25(OH)(2)D3) induces α-1-antitrypsin synthesis by CD4(+) T cells, which is required for 1,25(OH)(2)D3-driven IL-10
por: Dimeloe, Sarah, et al.
Publicado: (2019)

Anticancer activity of sugiol against ovarian cancer cell line SKOV3 involves mitochondrial apoptosis, cell cycle arrest and blocking of the RAF/MEK/ERK signalling pathway
por: Wang, Yan, et al.
Publicado: (2017)

Aurora-A overexpression enhances cell-aggregation of Ha-ras transformants through the MEK/ERK signaling pathway
por: Tseng, Ya-Shih, et al.
Publicado: (2009)

RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy
por: Yajima, Ichiro, et al.
Publicado: (2012)

Cardiac Hormones Target the Ras-MEK 1/2-ERK 1/2 Kinase Cancer Signaling Pathways
por: Vesely, David L.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_blikvb6ehmuvbq4ei1tt0iqdfs